Healthcare Industry News:  King Pharmaceuticals 

Biopharmaceuticals Personnel

 News Release - August 14, 2007

Affymax(R) Names Robert F. Venteicher, Ph.D., Vice President, Technical Operations

PALO ALTO, Calif.--(HSMN NewsFeed)--Affymax, Inc. (Nasdaq:AFFY ) today announced that Robert F. Venteicher, Ph.D. has joined the company as vice president, Technical Operations. Dr. Venteicher has nearly 30 years of experience in pharmaceutical and biotechnology drug development. In this position, Dr. Venteicher will oversee manufacturing and process development, quality and facility operations for Affymax.

Dr. Venteicher is experienced in managing supply chain and quality strategies for contracted and collaborative business alliances for development and commercial products sourced globally. His drug development experience includes work on vaccines, antibodies, recombinant proteins, toxins, small molecule organics and peptides in the therapeutic areas of oncology, and cardiovascular, neurologic, infectious and inflammatory diseases.

"Bob's extensive experience maKing Pharmaceuticals and biologics and ramping up commercial manufacturing will provide critical expertise and management as we advance Hematide(TM) through to commercialization," said Robert Naso, Ph.D., executive vice president, Research and Development at Affymax.

Dr. Venteicher joined Affymax from Elan Pharmaceuticals, Inc., where he held a number of positions, most recently as vice president, R&D Quality and Compliance. Prior to that, he served as vice president, Quality Assurance/Quality Control at Univax Biologics, Inc. Earlier in his career, he held the positions of head, R&D Pharmaceutical Quality Control and associate director of Bioprocess and Analytical Development at Centocor Inc. He also held scientific and management positions with increasing responsibilities during his 10-year tenure at Hoffmann LaRoche, Inc.

Dr. Venteicher received his B.S. in chemistry from Iowa State University and his Ph.D. in chemistry from Pennsylvania State University. He completed postdoctoral training in biochemistry and biophysics at Johnson Research Foundation, University of Pennsylvania.

About Affymax, Inc.

Affymax, Inc. is a biopharmaceutical company developing novel drugs to improve the treatment of serious and often life-threatening conditions. Affymax's lead product candidate, Hematide(TM), is currently in Phase 3 clinical trial stage for the treatment of anemia associated with chronic renal failure and in clinical trials for the treatment of anemia in cancer patients. For additional information, please visit www.affymax.com.

This release contains forward-looking statements, including statements regarding the timing, design and results of the Company's clinical trials and drug development program. The Company's actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties, including risks relating to the continued safety and efficacy of Hematide in clinical development, regulatory requirements and approvals, research and development efforts, industry and competitive environment, intellectual property rights and disputes and other matters that are described in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to update any forward-looking statement in this press release.


Source: Affymax

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.